LIMES Schlosskliniken (LIK) H1 2024 earnings summary

Executive summary

• Revenues rose 32% year-over-year to €18.7 million for the first half of 2024, driven by a 40% increase in patient days and strong occupancy rates across clinics.

• EBITDA increased 22% to €3.52 million, while EBIT grew 23% to €2.22 million, despite start-up costs for new locations.

• Net income attributable to shareholders nearly doubled to €1.83 million, with EPS up 92% to €6.24.

• The Clinicum Alpinum in Liechtenstein was consolidated for the first time, contributing to growth.

• Focus remains on completing new clinics at Abtsee and Lindlar, with further expansion expected in 2025.

Financial highlights

• Total revenues: €18.71 million (up 32.2% year-over-year).

• EBITDA: €3.52 million (up 22.2%), EBITDA margin 18.8%.

• EBIT: €2.22 million (up 23.1%), EBIT margin 11.8%.

• Net income for shareholders: €1.83 million (up 92.5%).

• Liquid assets: €7.83 million (up 25.3%).

Outlook and guidance

• Positive business trend expected to continue in the second half of 2024.

• Completion of Abtsee clinic expected by year-end; Lindlar property handover scheduled for early 2025.

• Start of operations at new locations projected to significantly increase revenue and EBITDA in the medium term.